ST Pharm Co.Ltd (237690) - Total Assets
Based on the latest financial reports, ST Pharm Co.Ltd (237690) holds total assets worth ₩782.57 Billion KRW (≈ $530.33 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 237690 total equity for net asset value and shareholders' equity analysis.
ST Pharm Co.Ltd - Total Assets Trend (2015–2025)
This chart illustrates how ST Pharm Co.Ltd's total assets have evolved over time, based on quarterly financial data.
ST Pharm Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
ST Pharm Co.Ltd's total assets of ₩782.57 Billion consist of 47.6% current assets and 52.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 3.9% |
| Accounts Receivable | ₩96.66 Billion | 12.4% |
| Inventory | ₩169.47 Billion | 21.7% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.20 Billion | 0.7% |
| Goodwill | ₩11.81 Billion | 1.5% |
Asset Composition Trend (2015–2025)
This chart illustrates how ST Pharm Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of ST Pharm Co.Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ST Pharm Co.Ltd's current assets represent 47.6% of total assets in 2025, an increase from 37.6% in 2015.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2025, down from 5.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 21.7% of total assets.
ST Pharm Co.Ltd Competitors by Total Assets
Key competitors of ST Pharm Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
KPX Lifescience.Co.Ltd
KQ:114450
|
Korea | ₩50.34 Billion |
|
GeneBioTech Co. Ltd
KQ:086060
|
Korea | ₩75.43 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩87.88 Billion |
|
Huons Global Co. Ltd
KQ:084110
|
Korea | ₩1.47 Trillion |
ST Pharm Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.26 | 2.48 | 9.90 |
| Quick Ratio | 1.23 | 1.52 | 7.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩207.92 Billion | ₩196.80 Billion | ₩206.44 Billion |
ST Pharm Co.Ltd - Advanced Valuation Insights
This section examines the relationship between ST Pharm Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.82 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.4% |
| Total Assets | ₩782.57 Billion |
| Market Capitalization | $1.93 Billion USD |
Valuation Analysis
Below Book Valuation: The market values ST Pharm Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ST Pharm Co.Ltd's assets grew by 8.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ST Pharm Co.Ltd (2015–2025)
The table below shows the annual total assets of ST Pharm Co.Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩782.57 Billion ≈ $530.33 Million |
+8.41% |
| 2024-12-31 | ₩721.88 Billion ≈ $489.20 Million |
+6.88% |
| 2023-12-31 | ₩675.44 Billion ≈ $457.73 Million |
+18.36% |
| 2022-12-31 | ₩570.65 Billion ≈ $386.72 Million |
+14.46% |
| 2021-12-31 | ₩498.57 Billion ≈ $337.87 Million |
+11.89% |
| 2020-12-31 | ₩445.57 Billion ≈ $301.96 Million |
+30.63% |
| 2019-12-31 | ₩341.08 Billion ≈ $231.15 Million |
-1.28% |
| 2018-12-31 | ₩345.51 Billion ≈ $234.14 Million |
-9.44% |
| 2017-12-31 | ₩381.50 Billion ≈ $258.54 Million |
+3.73% |
| 2016-12-31 | ₩367.78 Billion ≈ $249.24 Million |
+58.27% |
| 2015-12-31 | ₩232.37 Billion ≈ $157.47 Million |
-- |
About ST Pharm Co.Ltd
ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It… Read more